U.S. Artificial Retina Market Size, Share & Forecast 2026–2032

ID: MR-11060 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Artificial Retina
  • ✓Market Size 2024: USD 38.5 million
  • ✓Market Size 2032: USD 112.0 million
  • ✓CAGR: 14.3%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Argus II Legacy Stranded: Second Sight's Argus II won FDA Humanitarian Device Exemption authorization in 2013, but the company ended commercial support in 2022. U.S. recipients now rely on limited maintenance capacity, leaving no active domestic sponsor for the only FDA-authorized retinal prosthesis.
FINDING 02
Subretinal Designs Gaining Ground: Conventional wisdom holds that epiretinal designs define the category. Science Corporation's PRIMA subretinal chip, acquired from Pixium Vision, has shifted momentum toward subretinal systems that avoid external cabling and restore clinically meaningful functional vision in most trial participants.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Academic Trial Partnerships: Device developers and hospital investors should secure an IDE-approved trial partnership with a leading academic eye center by Q4 2026. Early U.S. enrollment strengthens TCET coverage eligibility, and late entrants will lose years of market access.

Artificial Retinas in the United States: Market Overview

The U.S. artificial retina market is a clinical-stage niche within ophthalmic devices, valued at an estimated USD 38.5 million in 2024 and forecast to reach USD 112.0 million by 2032. Unlike the global market, where demand spreads across broader retinal disease categories and multiple geographies, U.S. activity centers on retinitis pigmentosa and other inherited retinal dystrophies affecting roughly 100,000 Americans. Revenue arrives through individual implant procedures and trial milestones rather than recurring consumables.

Argus II, developed by Second Sight Medical Products, received Humanitarian Device Exemption authorization from the FDA in 2013 and remains the only retinal prosthesis that has reached U.S. patients commercially. Second Sight's 2022 withdrawal from commercial support left the category without an active domestic sponsor, forcing the market to rebuild around subretinal and suprachoroidal designs. Consequently, the market structure is defined by pipeline assets and academic trial sites rather than established supplier revenue.

Growth Drivers Behind Artificial Retinas in the United States

Three demand drivers are shaping the U.S. market. First, the National Eye Institute, operating on an annual budget of roughly USD 900 million, funds sustained inherited retinal disease research at centers including the Wilmer Eye Institute at Johns Hopkins and the Cole Eye Institute at Cleveland Clinic. Second, retinitis pigmentosa prevalence near 1 in 4,000 Americans creates a durable eligible pool, while advanced dry age-related macular degeneration affecting over one million Americans offers a longer-term expansion pathway.

Third, regulatory acceleration is lowering the cost of reaching market. FDA's Breakthrough Devices Program, codified under the 21st Century Cures Act of 2016, gives sponsors priority interaction with CDRH reviewers. CMS's Transitional Coverage for Emerging Technologies pathway, finalized in 2024, provides a route to Medicare coverage for designated breakthrough devices while evidence matures, shortening the gap between pivotal data and paid utilization.

Market Restraints and Entry Barriers

Regulatory structure is the dominant barrier. Most new retinal prostheses must complete a pivotal study under an Investigational Device Exemption governed by 21 CFR Part 812 and secure premarket approval under 21 CFR Part 814. The Humanitarian Device Exemption pathway offers a shortcut but caps annual distribution at 8,000 devices and cannot support broad commercial revenue, limiting its value for a full national launch.

Clinical infrastructure and reimbursement form the second barrier. Implantation requires specialized vitreoretinal surgeons working at a limited network of qualified U.S. centers, and patient selection depends on residual retinal architecture that many candidates lack. Entrants must also align with the Quality Management System Regulation, effective February 2, 2026, which aligns 21 CFR Part 820 with ISO 13485, and secure Medicare Part B coding before hospitals commit operating room time.

Market Opportunities for Artificial Retinas in the United States

The most immediate opportunity is a subretinal platform entering U.S. pivotal evaluation. Science Corporation's PRIMA system has a plausible U.S. addressable base of roughly 15,000 to 20,000 Americans with severe retinitis pigmentosa who retain light perception, according to analyst estimates derived from NEI prevalence data. Securing Breakthrough designation and early IDE sites in the Northeast and Midwest would position a launch around 2028.

A second opportunity lies in service and reactivation. Argus II recipients still require device maintenance, and U.S. patients whose systems lost support need explant, replacement, or upgrade pathways. Veterans Affairs medical centers, which procure specialty ophthalmic equipment through national contracting, represent a further channel with predictable procurement cycles and a veteran population affected by inherited and trauma-related retinal disease.

Market at a Glance

MetricValue
Market Size 2024USD 38.5 million
Market Size 2032USD 112.0 million
Growth Rate (CAGR)14.3%
Most Critical Decision FactorFDA marketing pathway and Medicare reimbursement coverage
Largest RegionNortheast and Midwest academic eye centers
Competitive StructureFragmented, pre-commercial, with few FDA-authorized devices

Leading Market Participants

  • Second Sight Medical Products
  • Science Corporation
  • Pixium Vision
  • Retina Implant AG
  • Nanoretina
  • Bionic Vision Technologies
  • Optobionics
  • Wilmer Eye Institute
  • Doheny Eye Institute
  • Cole Eye Institute

Regulatory and Policy Environment

FDA's Center for Devices and Radiological Health supervises retinal prosthesis filings under the Federal Food, Drug, and Cosmetic Act. Investigational studies follow 21 CFR Part 812, with IDE decisions due within 30 days, while Humanitarian Device Exemption requests fall under 21 CFR Part 814 Subpart H with a 75-day review target. Premarket approval reviews run on a nominal 180-day clock but typically extend to 12 months or more once major deficiencies are resolved.

Reimbursement and funding policy complete the framework. CMS administers Medicare Part B coverage, and its Transitional Coverage for Emerging Technologies pathway, finalized in 2024, allows up to five designated breakthrough devices per year to receive provisional coverage with evidence development. MDUFA V user fees fund FDA review staffing through fiscal 2027, while NEI's roughly USD 900 million annual budget supports the basic science feeding the device pipeline.

Long-Term Outlook for Artificial Retinas in the United States

By 2032, the U.S. artificial retina market is expected to shift from a single-device, academic-trial category into a small commercial market anchored by one or two subretinal or suprachoroidal systems. Revenue of USD 112.0 million reflects roughly 500 implant procedures annually across eligible centers, with per-procedure economics improved by TCET coverage and standardized surgical protocols.

Competitive dynamics will hinge on whether a subretinal leader converts PRIMA trial outcomes into U.S. approval before 2029, and whether Retina Implant AG's Alpha AMS and Nanoretina's designs achieve comparable durability. Hospital systems will consolidate implant programs around three to five regional centers, and device-service contracts will become a recurring revenue layer for manufacturers that survive the transition.

Frequently Asked Questions

Second Sight ended commercial support for Argus II in 2022, so new implants are not realistically available. Existing recipients depend on limited maintenance and replacement capacity.
Most new devices require an IDE-supported pivotal study followed by premarket approval. The Humanitarian Device Exemption applies only to rare disease populations and is capped at 8,000 devices annually.
Medicare Part B covers implants under established coding, and the TCET pathway can provide provisional coverage for designated breakthrough devices. Hospitals should confirm facility and professional codes before committing to a program.
Entrants typically need five to seven years from first-in-human work to commercial launch. Early IDE site partnerships and Breakthrough designation are the largest controllable accelerators.
A licensing or co-development agreement with a U.S. academic center and an experienced distributor reduces capital exposure. Direct subsidiary entry is viable only after pivotal data are in hand.

Market Segmentation

By Technology
  • Epiretinal
  • Subretinal
  • Suprachoroidal
  • Optogenetic Therapy
By End User
  • Academic Medical Centers
  • Ophthalmic Hospitals
  • Veterans Affairs Medical Centers
  • Ambulatory Surgery Centers
By Indication
  • Retinitis Pigmentosa
  • Stargardt Disease
  • Choroideremia
  • Geographic Atrophy

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Artificial Retina - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Technology Insights
4.1 Epiretinal
4.2 Subretinal
4.3 Suprachoroidal
4.4 Optogenetic Therapy
4.5 Others
Chapter 05 End User Insights
5.1 Academic Medical Centers
5.2 Ophthalmic Hospitals
5.3 Veterans Affairs Medical Centers
5.4 Ambulatory Surgery Centers
5.5 Others
Chapter 06 Indication Insights
6.1 Retinitis Pigmentosa
6.2 Stargardt Disease
6.3 Choroideremia
6.4 Geographic Atrophy
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Second Sight Medical Products
7.2.2 Science Corporation
7.2.3 Pixium Vision
7.2.4 Retina Implant AG
7.2.5 Nanoretina
7.2.6 Bionic Vision Technologies
7.2.7 Optobionics
7.2.8 Wilmer Eye Institute
7.2.9 Doheny Eye Institute
7.2.10 Cole Eye Institute
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.